About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2023№5
Prolonged hormonal therapy for endometriosis:...

Prolonged hormonal therapy for endometriosis: how to make the right choice?

DOI
https://dx.doi.org/10.18565/aig.2023.118

Chernukha G.E., Pronina V.A.

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia
From the modern perspective, endometriosis is a chronic hormone-dependent disease tending to progress and recur, including after earlier surgical treatment. лечения. In view of this, a search for the optimal drug therapy that prevents relapses and that is effective and safe in its prolonged use is relevant. The paper reviews the Russian and foreign sources demonstrating the expendiency of using dienogest as a first-line therapy for endometriosis. One of the advantages of this progestagen is its pleiotropic mechanism of action, which directly or indirectly contributing to a decrease in the activity of endometrioid foci. Furthermore, the paper presents the data demonstrating the advantages of using dienogest both from the standpoint of prolonged therapy for different forms of endometriosis and in comparison with other drug treatments with gonadotropin-releasing hormone agonists, combined oral contraceptives, the levonorgestrel-containing intrauterine system, and other agents.
Conclusion: As of now, surgical and medical treatments for endometriosis are not contrasted, but complement each other. It is extremely important in the context of a decline in the rate of postoperative relapses, an improvement in life quality in the women, and a reduction in the risk of polycystic ovary syndrome. To date, dienogest is the drug of choice for good reason for prolonged therapy for endometriosis in view of not only the high activity of the drug against different forms of endometriosis, but also its safety during prolonged use.

Authors' contributions: Pronina V.A. – material collection and processing; Pronina V.A., Chernukha G.E. – writing the text; Chernukha G.E. – editing.
Conflicts of interest: The authors declare that there are no possible conflicts of interest.
Funding: The investigation has not been sponsored.
For citation: Chernukha G.E., Pronina V.A.
Prolonged hormonal therapy for endometriosis: how to make the right choice?
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2023; (5): 132-139 (in Russian)
https://dx.doi.org/10.18565/aig.2023.118

Keywords

endometriosis
hormonal suppressive hormone therapy
dienogest
prolonged therapy
prevention of recurrences
Full text (in Russian)

References

  1. Kennedy S., Bergqvist A., Chapron C., D'Hooghe T., Dunselman G., Greb R. et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum. Reprod. 2005; 20: 2698-704.
  2. Moradi Y., Shams-Beyranvand M., Khateri S., Gharahjeh S., Tehrani S., Varse F. et al. A systematic review on the prevalence of endometriosis in women. Indian J. Med. Res. 2021; 154(3): 446-54. https://dx.doi.org/10.4103/ijmr.IJMR_817_18.
  3. Becker C.M., Bokor A., Heikinheimo O., Horne A., Jansen F. et al.; ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. Hum. Reprod. Open. 2022; 2022(2): hoac009. https://dx.doi.org/10.1093/hropen/hoac009.
  4. Chapron C., Marcellin L., Borghese B., Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat. Rev. Endocrinol. 2019; 15(11): 666-82. https://dx.doi.org/10.1038/s41574-019-0245-z.
  5. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Эндометриоз. М.; 2020. [Ministry of Health of the Russian Federation. Clinical guidelines. Endometriosis. Moscow; 2020. (in Russian)]. Available at: https://cr.minzdrav.gov.ru/recomend/259_1
  6. NICE Endometriosis: diagnosis and management. (NG73). NICE guideline. 6 September 2017. Available at: https://www.nice.org.uk/guidance/ng73
  7. Ceccaroni M., Bounous V.E., Clarizia R., Mautone D., Mabrouk M. Recurrent endometriosis: a battle against an unknown enemy. Eur. J. Contracept. Reprod. Health Care. 2019; 24(6): 464-74.https://dx.doi.org/10.1080/13625187.2019.1662391.
  8. Shakiba K., Bena J.F., McGill K.M., Minger J., Falcone T. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. Obstet. Gynecol. 2008; 111(6): 1285-92. https://dx.doi.org/10.1097/AOG.0b013e3181758ec6.
  9. Nirgianakis K., Ma L., McKinnon B., Mueller M.D. Recurrence patterns after surgery in patients with different endometriosis subtypes: a long-term hospital-based cohort study. J. Clin. Med. 2020; 9(2): 496. https://dx.doi.org/10.3390/jcm9020496.
  10. Moreno-Sepulveda J., Romeral C., Niño G., Pérez-Benavente A. The effect of laparoscopic endometrioma surgery on anti-müllerian hormone: a systematic review of the literature and meta-analysis. JBRA Assist. Reprod. 2022; 26(1): 88-104. https://dx.doi.org/10.5935/1518-0557.20210060.
  11. Muzii L., Achilli C., Lecce F., Bianchi A., Franceschetti S., Marchetti C. et al. Second surgery for recurrent endometriomas is more harmful to healthy ovarian tissue and ovarian reserve than first surgery. Fertil. Steril. 2015; 103(3): 738-43. https://dx.doi.org/10.1016/j.fertnstert.2014.12.101.
  12. Irahara M., Harada T., Momoeda M., Tamaki Y. Hormonal and histological study on irregular genital bleeding in patients with endometriosis during treatment with dienogest, a novel progestational therapeutic agent. Reprod. Med. Biol. 2007; 6(4): 223-8. https://dx.doi.org/10.1111/j.1447-0578.2007.00189.x.
  13. Miyashita M., Koga K., Takamura M., Izumi G., Nagai M., Harada M. et al. Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol. Endocrinol. 2014; 30(9): 644-8. https://dx.doi.org/10.3109/09513590.2014.911279.
  14. Kim H.J., Kim S.H., Oh Y.S., Lee S.R., Chae H.D. Dienogest may reduce estradiol- and inflammatory Cytokine-induced cell viability and proliferation and inhibit the pathogenesis of endometriosis: a cell culture- and mouse model-based study. Biomedicines. 2022; 10(11): 2992. https://dx.doi.org/10.3390/biomedicines10112992.
  15. Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil. Steril. 2014; 101(4): 927-35. https://dx.doi.org/10.1016/j.fertnstert.2014.02.012.
  16. Shimizu Y., Takeuchi T., Mita S., Mizuguchi K., Kiyono T., Inoue M., Kyo S. Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression. Mol. Hum. Reprod. 2009; 15(10): 693-701. https://dx.doi.org/10.1093/molehr/gap042.
  17. Göhring J., Drewes M., Kalder M., Kostev K. Germany endometriosis pattern changes; prevalence and therapy over 2010 and 2019 years: a retrospective cross-sectional study. Int. J. Fertil. Steril. 2022; 16(2): 85-9.https://dx.doi.org/10.22074/IJFS.2021.528397.1113.
  18. Heinemann K., Imthurn B., Marions L., Gerlinger C., Becker K., Moehner S., Faustmann T. Safety of dienogest and other hormonal treatments for endometriosis in real-world clinical practice (VIPOS): a large noninterventional ssudy. Adv. Ther. 2020; 37(5): 2528-37. https://dx.doi.org/10.1007/s12325-020-01331-z.
  19. Techatraisak K., Hestiantoro A., Soon R., Banal-Silao M.J., Kim M.R.,Seong S.J. et al. Impact of long-term dienogest therapy on quality of life in Asian women with endometriosis: the prospective non-interventional study ENVISIOeN. Reprod. Sci. 2022; 29(4): 1157-69. https://dx.doi.org/10.1007/s43032-021-00787-w.
  20. Liu Y., Gong H., Gou J., Liu X., Li Z. Dienogest as a maintenance treatment for endometriosis following surgery: a systematic review and meta-analysis. Front. Med. (Lausanne). 2021; 8: 652505. https://dx.doi.org/10.3389/fmed.2021.652505.
  21. Lee S.R., Yi K.W., Song J.Y., Seo S.K., Lee D.Y., Cho S., Kim S.H. Efficacy and safety of long-term use of dienogest in women with ovarian endometrioma. Reprod. Sci. 2017; 25(3): 341-6. https://dx.doi.org/10.1177/1933719117725820.
  22. Choi S.H., Kim S., Lee S.W., Won S., Shim S.H., Lee N. et al. Recurrence, reoperation, pregnancy rates, and risk factors for recurrence after ovarian endometrioma surgery: long-term follow-Up of 756 women. Yonsei Med. J. 2023; 64(3): 204-12. https://dx.doi.org/10.3349/ymj.2022.0278.
  23. Barra F., Scala C., Maggiore U.L.R., Ferrero S. Long-term administration of dienogest for the treatment of pain and intestinal symptoms in patients with rectosigmoid endometriosis. J. Clin. Med. 2020; 9(1): 154.https://dx.doi.org/10.3390/jcm9010154.
  24. Yamanaka A., Hada T., Matsumoto T., Kanno K., Shirane A., Yanai S. et al. Effect of dienogest on pain and ovarian endometrioma occurrence after laparoscopic resection of uterosacral ligaments with deep infiltrating endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017; 216: 51-5. https://dx.doi.org/10.1016/j.ejogrb.2017.07.014.
  25. Zakhari A., Delpero E., McKeown S., Tomlinson G., Bougie O., Murji A. Endometriosis recurrence following post-operative hormonal suppression: a systematic review and meta-analysis. Hum. Reprod. Update. 2021; 27(1): 96-107. https://dx.doi.org/10.1093/humupd/dmaa033.
  26. Takaesu Y., Nishi H., Kojima J., Sasaki T., Nagamitsu Y., Kato R., Isaka K. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis. J. Obstet. Gynaecol. Res. 2016; 42(9): 1152-8. https://dx.doi.org/10.1111/jog.13023.
  27. Chiu C.C., Hsu T.F., Jiang L.Y., Chan I.S., Shih Y.C., Chang Y.H. et al. Maintenance therapy for preventing endometrioma recurrence after endometriosis resection surgery - a systematic review and network meta-analysis. J. Minim. Invasive Gynecol. 2022; 29(5): 602-12. https://dx.doi.org/10.1016/j.jmig.2021.11.024.
  28. Ceccaroni M., Clarizia R., Liverani S., Donati A., Ceccarello M., Manzone M. et al. Dienogest vs GnRH agonists as postoperative therapy after laparoscopic eradication of deep infiltrating endometriosis with bowel and parametrial surgery: a randomized controlled trial. Gynecol. Endocrinol. 2021; 37(10):930-3. https://dx.doi.org/10.1080/09513590.2021.1929151.
  29. Ozaki R., Kumakiri J., Jinushi M., Ikuma S., Murakami K., Kawasaki Y., Kitade M. Comparison of effect of preoperative dienogest and gonadotropin-releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas. Arch. Gynecol. Obstet. 2020; 302(4): 969-76.https://dx.doi.org/10.1007/s00404-020-05691-3.
  30. Muraoka A., Osuka S., Yabuki A., Bayasula, Yoshihara M., Tanaka H. et al. Impact of perioperative use of GnRH agonist or dienogest on ovarian reserve after cystectomy for endometriomas: a randomized controlled trial. Reprod. Biol. Endocrinol. 2021; 19(1): 179. https://dx.doi.org/10.1186/s12958-021-00866-2.
  31. El Taha L., Abu Musa A., Khalifeh D., Khalil A., Abbasi S., Nassif J. Efficacy of dienogest vs combined oral contraceptive on pain associated with endometriosis: Randomized clinical trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 2021; 267: 205-12. https://dx.doi.org/10.1016/j.ejogrb.2021.10.029.
  32. Mehdizadeh Kashi A., Niakan G., Ebrahimpour M., Allahqoli L., Hassanlouei B., Gitas G., Alkatout I. A randomized, double-blind, placebo-controlled pilot study of the comparative effects of dienogest and the combined oral contraceptive pill in women with endometriosis. Int. J. Gynaecol. Obstet. 2022; 156(1): 124-32. https://dx.doi.org/10.1002/ijgo.13677.
  33. Choi S.H., Kim S.E., Lim H.H., Lee D.Y., Choi D. Efficacy of post-operative medication to prevent recurrence of endometrioma: cyclic oral contraceptive (OC) after gonadotropin-releasing hormone (GnRH) agonist versus dienogest. J. Korean Med. Sci. 2022; 37(26): e207. https://dx.doi.org/10.3346/jkms.2022.37.e207.
  34. Uysal G., Akkaya H., Cagli F., Tutus S., Tayyar A.T. A comparison of two different oral contraceptives in patients with severe primary dysmenorrhoea. J. Obstet. Gynaecol. 2018; 38(6): 828-32. https://dx.doi.org/10.1080/01443615.2017.1410533.
  35. Caruso S., Iraci M., Cianci S., Fava V., Casella E., Cianci A. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J. Endocrinol. Invest. 2016; 39(8): 923-31. https://dx.doi.org/10.1007/s40618-016-0460-6.
  36. Piacenti I., Viscardi M.F., Masciullo L., Sangiuliano C., Scaramuzzino S., Piccioni M.G. et al. Dienogest versus continuous oral levonorgestrel/EE in patients with endometriosis: what's the best choice? Gynecol. Endocrinol. 2021; 37(5): 471-5. https://dx.doi.org/10.1080/09513590.2021.1892632.
  37. Angioni S., Pontis A., Malune M.E., Cela V., Luisi S., Litta P. et al. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecol. Endocrinol. 2020; 36(1): 84-6. https://dx.doi.org/10.1080/09513590.2019.1640674.
  38. Mitchell J.B., Chetty S., Kathrada F. Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety. BMC Womens Health. 2022; 22(1): 526. https://dx.doi.org/10.1186/s12905-022-02122-0.
  39. Del Forno S., Mabrouk M., Arena A., Mattioli G., Giaquinto I., Paradisi R., Seracchioli R. Dienogest or norethindrone acetate for the treatment of ovarian endometriomas: can we avoid surgery? Eur. J. Obstet. Gynecol. Reprod. Biol. 2019; 238: 120-4. https://dx.doi.org/10.1016/j.ejogrb.2019.04.010.
  40. Vercellini P., Bracco B., Mosconi P., Roberto A., Alberico D., Dhouha D., Somigliana E. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil. Steril. 2016; 105(3): 734-743.e3. https://dx.doi.org/10.1016/j.fertnstert.2015.11.016.
  41. Sukhikh G.T., Adamyan L.V., Dubrovina S.O., Baranov I.I., Bezhenar V.F., Kozachenko A.V., Radzinsky V.E., Orazov M.R., Yarmolinskaya M.I., Olofsson J.I. Prolonged cyclical and continuous regimens of dydrogesterone are effective for reducing chronic pelvic pain in women with endometriosis: results of the ORCHIDEA study. Fertil. Steril. 2021; 116(6): 1568-77.https://dx.doi.org/10.1016/j.fertnstert.2021.07.1194.
  42. Peng C., Huang Y., Zhou Y. Dydrogesterone in the treatment of endometriosis: evidence mapping and meta-analysis. Arch. Gynecol. Obstet. 2021; 304(1): 231-52. https://dx.doi.org/10.1007/s00404-020-05900-z.
  43. Morelli M., Sacchinelli A., Venturella R., Mocciaro R., Zullo F. Postoperative administration of dienogest plus estradiol valerate versus levonorgestrel-releasing intrauterine device for prevention of pain relapse and disease recurrence in endometriosis patients. J. Obstet. Gynaecol. Res. 2013; 39(5): 985-90.https://dx.doi.org/10.1111/jog.12030.
  44. Bayoglu Tekin Y., Dilbaz B., Altinbas S.K., Dilbaz S. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil. Steril. 2011; 95(2): 492-6. https://dx.doi.org/10.1016/j.fertnstert.2010.08.042.
  45. Gibbons T., Georgiou E.X., Cheong Y.C., Wise M.R. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. Cochrane Database Syst. Rev. 2021; 12(12): CD005072.https://dx.doi.org/10.1002/14651858.CD005072.pub4.
  46. Аполихина И.А., Тарнаева Л.А., Кондратьева Н.Е. Результаты исследований биоэквивалентности препаратов диеногеста, прогестерона, левоноргестрела+эстрадиол у здоровых добровольцев после однократного приема натощак. Акушерство и гинекология. 2023; 1: 110-21. [Apolikhina I.A., Tarnaeva L.A., Kondratyeva N.E. Results of bioequivalence studies on dienogest, progesterone, and levonorgestrel+estradiol in healthy volunteers after single dose intake during fasting. Obstetrics and Gynecology. 2023; (1): 110-21. (in Russian)]. https://dx.doi.org/10.18565/aig.2022.304.

Received 10.05.2023

Accepted 12.05.2023

About the Authors

Galina E. Chernukha, Dr. Med. Sci., Professor, Chief Researcher, obstetrician-gynecologist at the Department of Gynecological Endocrinology, Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, +7(985)999-60-00, c-galina1@yandex.ru,
https://orcid.org/0000-0002-9065-5689, 117997, Russia, Moscow, Ac. Oparin str., 4.
Veronika A. Pronina, obstetrician-gynecologist, PhD student, Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology,
Ministry of Health of Russia, +7(916)025-86-26, ver22595@yandex.ru, https://orcid.org/0000-0003-4566-4065, 117997, Russia, Moscow, Ac. Oparin str., 4.
Corresponding author: Galina E. Chernukha, c-galina1@yandex.ru

Similar Articles

№10 / 2023
Rukhliada N.N.
The effectiveness of the administration regimen of Вuserelin-depo with a prolonged interval between injections: hormonal profile and acceptability of treatment for patients with endometriosis
№6 / 2024
Chernukha G.E., Solopova A. E., Pronina V.A.
New possibilities for assessing the magnetic resonance characteristics of endometrioid ovarian cysts and their response to dienogest therapy
№11 / 2023
Chernukha G.E., Pronina V.A., Solopova A.E.
Modern possibilities for optimizing the diagnosis and therapy of ovarian endometriomas
№1 / 2024
Sulima A.N., Gudz O.V.
Retrospective analysis of urgent gynecological laparoscopic surgery in patients of reproductive age
№4 / 2023
Pronina V.A., Dumanovskaya M.R., Chernukha G.E.
Principles of early diagnosis of endometriosis based on the assessment of comorbidity and clinical manifestations
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.